For example, the Y654 of CTNNB1 has a high score of 0.93, inhibiting its Phos by Imatinib offered a therapeutic value in patients with chronic myeloid leukemia (CML) (Coluccia et al., 2007), which was in accord with PTM-associated PPI network results (Fig. 2D and E). The gene discussed is CTNNB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.